Alexandre Giannecchini Romagnolo

Bachelor of Biomedical Sciences from the Institute of Biosciences of Botucatu UNESP (2016), and Masters degree in Research and Development in Medical Biotechnology from the Botucatu Medical School UNESP (2019). Earned a Ph.D. in Health Sciences from Hospital Israelita Albert Einstein in 2024 and is currently a postdoctoral fellow at the Instituto Israelita de Ensino e Pesquisa (IIEP), Hospital Israelita Albert Einstein. His current work focuses on the development of melanoma animal models to study immunotherapies using human T cells genetically modified by CRISPR/Cas9 to knock out exhaustion markers in tumor-infiltrating lymphocytes (TILs). His Ph.D. research focused on changes in the metabolomic profile and immune response during acute dengue infection. During his undergraduate studies, he participated in the Science Without Borders program (GS/CSF CAPES-funded), spending the year 2014 at Brown University (USA). In the final years of the degree, he focused on immunology, conducting research on the role of the Dectin-1 receptor in human monocytes during fungal infections. His Masters degree involved the development of immunosensor prototypes for the classification of human blood types. He has experience in cell culture, molecular biology, flow cytometry, monoclonal antibody production and purification, and immunosensor prototyping. (Source: Lattes Curriculum)